[go: up one dir, main page]

WO2005115470A3 - COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS - Google Patents

COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS Download PDF

Info

Publication number
WO2005115470A3
WO2005115470A3 PCT/FR2005/001082 FR2005001082W WO2005115470A3 WO 2005115470 A3 WO2005115470 A3 WO 2005115470A3 FR 2005001082 W FR2005001082 W FR 2005001082W WO 2005115470 A3 WO2005115470 A3 WO 2005115470A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
pharmaceutical compositions
carboline derivatives
carboline
Prior art date
Application number
PCT/FR2005/001082
Other languages
English (en)
Other versions
WO2005115470A2 (fr
Inventor
Nee Yanagida Akino Jossang
Georges Uzan
Jean Kenji Jossang
Original Assignee
Centre Nat Rech Scient
Nee Yanagida Akino Jossang
Georges Uzan
Jean Kenji Jossang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Nee Yanagida Akino Jossang, Georges Uzan, Jean Kenji Jossang filed Critical Centre Nat Rech Scient
Priority to EP05767476A priority Critical patent/EP1740212A2/fr
Priority to US11/587,852 priority patent/US20080069899A1/en
Priority to JP2007510083A priority patent/JP2007535525A/ja
Publication of WO2005115470A2 publication Critical patent/WO2005115470A2/fr
Publication of WO2005115470A3 publication Critical patent/WO2005115470A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'au moins un composé de formule générale (1) pour la préparation d'un médicament destiné au traitement des cancers.
PCT/FR2005/001082 2004-04-30 2005-04-29 COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS WO2005115470A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05767476A EP1740212A2 (fr) 2004-04-30 2005-04-29 Compositions pharmaceutiques contenant des derives de beta­carboline, et leur utilisation pour le traitement des cancers
US11/587,852 US20080069899A1 (en) 2004-04-30 2005-04-29 Pharmaceutical Compositions Comprising Beta-Carboline Derivatives and Use Thereof for the Treatment of Cancer
JP2007510083A JP2007535525A (ja) 2004-04-30 2005-04-29 β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR04/04646 2004-04-30
FR0404646A FR2869540B1 (fr) 2004-04-30 2004-04-30 Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers

Publications (2)

Publication Number Publication Date
WO2005115470A2 WO2005115470A2 (fr) 2005-12-08
WO2005115470A3 true WO2005115470A3 (fr) 2007-03-22

Family

ID=34950528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001082 WO2005115470A2 (fr) 2004-04-30 2005-04-29 COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS

Country Status (5)

Country Link
US (1) US20080069899A1 (fr)
EP (1) EP1740212A2 (fr)
JP (1) JP2007535525A (fr)
FR (1) FR2869540B1 (fr)
WO (1) WO2005115470A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
GB0705566D0 (en) * 2007-03-23 2007-05-02 Univ Dundee Method of treating learning impairment in down's syndrome subjects
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2010138652A1 (fr) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Méthodes de traitement du sarcome de kaposi
TW201100419A (en) 2009-05-27 2011-01-01 Ptc Therapeutics Inc Processes for the preparation of substituted tetrahydro beta-carbolines
WO2010138685A1 (fr) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Procédés pour traiter des troubles de la prostate
ES2360547B1 (es) * 2009-11-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso.
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
US20130165474A1 (en) * 2010-08-17 2013-06-27 Travis Dunckley Compounds that inhibit tau phosphorylation
EP2455378A1 (fr) * 2010-11-03 2012-05-23 Philip Morris Products S.A. Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées
US20160106687A1 (en) * 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
WO2016181220A2 (fr) * 2015-05-13 2016-11-17 Ions Pharmaceutical S.À R.L. Compositions thérapeutiques et méthodes d'utilisation de ces compositions
DK3188721T3 (da) * 2014-10-21 2019-08-12 Ankh Life Sciences Ltd Humane terapeutika
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CN112716947A (zh) * 2021-01-27 2021-04-30 新疆维吾尔自治区维吾尔医药研究所 从骆驼蓬中提取分离的γ-去氢骆驼蓬碱在制备抑制胃癌药物中的应用
CN115487184A (zh) * 2022-09-06 2022-12-20 南昌大学 去氢骆驼蓬碱在制备治疗结肠癌药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2140797A (en) * 1983-06-04 1984-12-05 Tanabe Seiyaku Co Tetrahydro-b-carboline derivatives
GB2303627B (en) * 1995-07-26 1997-07-09 Arab Pharmaceutical Mfg Co Ltd Anti-tumour platinum-harmine complex
CN1063966C (zh) * 1998-10-12 2001-04-04 王世渝 骆驼蓬制剂及制备方法
ATE541937T1 (de) * 2001-04-06 2012-02-15 Univ Chicago Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ISHIDA J ET AL: "Antitumor Agents 201. Cytotoxicity of Harmine and beta-Carboline Analogs", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 23, 6 December 1999 (1999-12-06), pages 3319 - 3324, XP004183731, ISSN: 0960-894X *
KUSURKAR R S ET AL: "Efficient one-pot synthesis of anti HIV and antitumor compounds: harman and substituted harmans", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 44, no. 25, 16 June 2003 (2003-06-16), pages 4761 - 4763, XP004426888, ISSN: 0040-4039 *
See also references of EP1740212A2 *
SONG Y ET AL: "Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 317, no. 1, 23 April 2004 (2004-04-23), pages 128 - 132, XP004496939, ISSN: 0006-291X *

Also Published As

Publication number Publication date
JP2007535525A (ja) 2007-12-06
EP1740212A2 (fr) 2007-01-10
FR2869540A1 (fr) 2005-11-04
US20080069899A1 (en) 2008-03-20
FR2869540B1 (fr) 2008-05-16
WO2005115470A2 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2005066163A3 (fr) Heterocycles substitues et leurs utilisations
WO2005075425A3 (fr) Derives de bisaryluree
WO2007096151A3 (fr) Composes organiques
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2006123113A3 (fr) Composes chimiques
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2006099943A8 (fr) 8-n-benzimidazoles a substitution amide, leur procede de production, et leur utilisation en tant que medicaments
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
WO2007123939A8 (fr) Nouveaux arylamino n-hétéraryles en tant qu'inhibiteurs de mek
WO2009016410A3 (fr) Composés chimiques 831
WO2006005609A3 (fr) Derives d'oxindole substitues, et medicaments les renfermant
WO2005037798A3 (fr) Nouveaux composés
WO2005040171A8 (fr) Derives de pyrazolo-pyrimidine et d'imidazo-pyrimidine
WO2007129066A8 (fr) (1-méthanesulfonyl-pipéridin-4-yl)-amide de l'acide 4-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylique pour le traitement du cancer
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
IL229594A (en) Derived Lactone Derivatives, Pharmaceutical Compositions Containing Them and Their Uses in the Preparation of Medical Preparations for Cancer Treatment
WO2006108488A8 (fr) Derives d'azole tricycliques, leur fabrication et leur utilisation en tant que principes pharmaceutiques
WO2004111008A3 (fr) Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005767476

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007510083

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005767476

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11587852

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11587852

Country of ref document: US